FNY Managed Accounts’s Cytokinetics CYTK Stock Holding History

FNY Managed Accounts’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-540	Closed	-$6K	–	268
2017 Q1	$6K	Buy	+540	New	+$6.31K	0.02%	583

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LPU

Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

FNY Managed Accounts's CYTK Position: Q2 2017 in Review

FNY Managed Accounts sold out of Cytokinetics (CYTK) in Q2 2017, closing a stake of 540 shares — an estimated $6K sold.

FNY Managed Accounts first reported a position in CYTK in Q1 2017 and held it in 1 quarter. The position peaked at $6K in Q1 2017. 136 funds tracked by Wall St. Rank hold CYTK as of Q2 2017.

FNY Managed Accounts reported no remaining Cytokinetics position as of Q2 2017 after selling out during the quarter.
FNY Managed Accounts sold 540 Cytokinetics shares in Q2 2017, an estimated $6K.
FNY Managed Accounts first reported a position in Cytokinetics in Q1 2017 and held it in 1 quarter.
FNY Managed Accounts's Cytokinetics position peaked at $6K in Q1 2017.
136 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2017.

Based on FNY Managed Accounts's 13F filing for Q2 2017, filed 10 Aug 2017.